Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
THE approval of Novartis's breakthrough therapy for a deadly form of leukaemia opened the door to a new class of treatments even as its US$475,000 price tag reignited the debate on how to value potentially life-saving drugs.
Demonstrating its willingness to clear